ESMO: Erdafitinib demonstrates improved responses in FGFR-altered advanced urinary tract cancers
ABSTRACTS: 2359O, 2362MO
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with metastatic urothelial cancers with FGFR alterations. Results from the Phase III THOR trial, led by researchers at The University of Texas MD Anderson Cancer Center, were reported at the 2023 European Society of Medical Oncology...
ESMO: PARP inhibitor plus immunotherapy lowers risk of endometrial cancer progression over chemotherapy alone
ABSTRACT: LBA41
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (...